Sample of Issued Patents derived from laboratory research:

1. U.S. patent,5,578,716 DNA methyltransferase antisense oligonucleotides

2. U. S. patent 5,5919,772 Antisense oligonucleotides having tumoreginicity inhibiting activity.

3. U. S. patent 6,054,439 antisense oligonucleotides having tumoreginicity inhibiting activity.

4. U. S. patent 6,184,211 Inhibition of DNA methyltransferase

5. 5. U. S. patent 6,066,625 Optimized antisense oligonucleotides complementary to DNA methyltransferase sequences.

6. Published PCT application: DNA demethylase therapeutic and diagnostic uses thereof PCT 1770-183.

Current projects in the laboratory;

Delineating the mechanisms responsible for cell cycle regulation of DNMT1
3'UTR elements and proteins interacting with them
involvement of cell cycle regulation of DNMT1 in tumorigenesis
Unraveling the mechanisms through which DNMT1 inhibitors block tumorigenesis
-methylation independent mechanisms of regulation of gene expression by DNMT1 inhibitors
-understanding the mechanisms through which DNMT1 regulates DNA replication

Deciphering mechanisms of active demethylation
-understanding the links between chromatin structure and demethylase
-structure function analysis of MBD2/demethylase
-mechanism of the demethylase reaction

Analyzing the role of demethylase, MBD2 and global demethylation in tumorigenesis and behavioral imprinting